NextCure Partners with Simcere for Novel ADC in $745M Deal
NextCure has partnered with Simcere to develop the ADC SIM0505, targeting CDH6 for solid tumors.
The deal includes an undisclosed upfront payment plus development, regulatory, and sales milestones up to $745 million.
NextCure will initiate a Phase I trial in the U.S. in the third quarter of 2025.
Simcere's proprietary payload is highlighted for its potential improved safety and efficacy profile.